The FDA approves Utebzi, boosting Spero Therapeutics, Inc. via GSK milestones and royalties. Click for more on SPRO stock and ...
GSK plc GSK and Spero Therapeutics, Inc. SPRO announced on Wednesday that the U.S. Food and Drug Administration has approved ...
InvestorsHub on MSN
Spero shares jump after FDA clears first oral carbapenem antibiotic for US market (SPRO)
Spero Therapeutics (NASDAQ:SPRO) shares climbed 16% on Thursday after the U.S. Food and Drug Administration approved Utebzi, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The average one-year price target for Spero Therapeutics (NASDAQ:SPRO) has been revised to 7.65 / share. This is an increase of 12.50% from the prior estimate of 6.80 dated October 31, 2023. The price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results